OncLive - October 8, 2021
"The FDA has granted a rare pediatric disease designation (RPDD) to lutetium-177(177Lu)-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma." Read Article>>
FDA Grants Rare Pediatric Disease Designation to 177Lu-Omburtamab-DTPA for Medulloblastoma